胰腺癌新辅助治疗的研究现状

doi:10.11904/j.issn.1002-3070.2022.01.012

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (1): 64-68.doi: 10.11904/j.issn.1002-3070.2022.01.012

胰腺癌新辅助治疗的研究现状

张文静, 刘金爽, 王丹, 黎清炜综述, 李志伟审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2021-03-04 修回日期:2021-05-06 出版日期:2022-02-28 发布日期:2022-01-21
通讯作者: 李志伟,E-mail:lzhw0451@163.com
作者简介:张文静,女,(1996-),硕士研究生,从事消化道肿瘤的研究。
基金资助:
国家自然科学基金面上资助项目(编号:81773210)

Research status of neoadjuvant therapy for pancreatic cancer

ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei

Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2021-03-04 Revised:2021-05-06 Online:2022-02-28 Published:2022-01-21

摘要/Abstract

摘要： 胰腺癌是消化系统恶性程度最高的肿瘤。近年来胰腺癌的发病率呈逐年上升趋势,预计在未来10年胰腺癌将成为发达国家癌症死亡的第二大原因。由于诊断时分期较晚,治疗选择有限,胰腺癌的预后极差,只有手术是治愈的唯一方法。为了提高手术切除率并改善预后,新辅助治疗已悄然成为目前胰腺癌治疗的热点问题。但现在胰腺癌的新辅助治疗还未有标准化的治疗方案,本文主要探讨胰腺癌新辅助治疗的研究现状。

关键词: 胰腺癌, 新辅助治疗, 新辅助化疗, 新辅助放化疗

Abstract: Pancreatic cancer is the most malignant tumor of the digestive system.In recent years,the incidence of pancreatic cancer has increasing year by year.It is expected that pancreatic cancer will become the second leading cause of cancer death in developed countries in the next decade.Due to the late diagnosis and limited treatment options,the prognosis of pancreatic cancer is extremely poor.Only surgery is the only way to cure.In order to increase the surgical resection rate and improve the prognosis,neoadjuvant therapy has quietly become a hot topic in the treatment of pancreatic cancer.However,there is no standardized treatment plan for neoadjuvant treatment of pancreatic cancer.This article mainly discusses the research status of neoadjuvant treatment of pancreatic cancer.

Key words: Pancreatic cancer, Neoadjuvant therapy, Neoadjuvant chemotherapy, Neoadjuvant chemoradiotherapy

中图分类号:

R735.9

张文静, 刘金爽, 王丹, 黎清炜, 李志伟. 胰腺癌新辅助治疗的研究现状[J]. 实用肿瘤学杂志, 2022, 36(1): 64-68.

ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei. Research status of neoadjuvant therapy for pancreatic cancer[J]. Journal of Practical Oncology, 2022, 36(1): 64-68.

参考文献

1 Lambert A,Schwarz L,Borbath I,et al.An update on treatment options for pancreatic adenocarcinoma[J].Ther Adv Med Oncol,2019,11:1758835919875568.
2 Saito K,Isayama H,Sakamoto Y,et al.A phase II trial of gemcitabine,S-1 and LV combination(GSL)neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer[J].Med Oncol,2018,35(7):100.
3 Napolitano F,Formisano L,Giardino A,et al.Neoadjuvant treatment in locally advanced pancreatic cancer(LAPC)patients with FOLFIRINOX or Gemcitabine NabPaclitaxel:a single-center experience and a literature review[J].Cancers(Basel),2019,11(7):981.
4 范晓娜,王丹,黎清炜,等.胰腺癌术后辅助药物治疗的研究进展[J].实用肿瘤学杂志,2020,34(3):249-253.
5 Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
6 Chen-Zhao X,Hernando O,López M,et al.A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy(SBRT)as a neoadjuvant strategy of chemoradiation in pancreatic cancer[J].Clin Transl Oncol,2020,22(9):1499-1505.
7 Motoi F,Kosuge T,Ueno H,et al.Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02/JSAP05)[J].Jpn J Clin Oncol,2019,49(2):190-194.
8 Seufferlein T,Ettrich TJ.Treatment of pancreatic cancer—neoadjuvant treatment in resectable pancreatic cancer(PDAC)[J].Transl Gastroenterol Hepatol,2019,4:21.
9 Motoi F,Unno M.Neoadjuvant treatment for resectable pancreatic adenocarcinoma:What is the best protocol?[J].Ann Gastroenterol Surg,2020,4(2):100-108.
10 Abi Jaoude J,Kouzy R,Nguyen ND,et al.Radiation therapy for patients with locally advanced pancreatic cancer:Evolving techniques and treatment strategies[J].Curr Probl Cancer,2020,44(6):100607.
11 Xiang M,Heestand GM,Chang DT,et al.Neoadjuvant treatment strategies for resectable pancreas cancer:a propensity-matched analysis of the national cancer database[J].Radiother Oncol,2020,143:101-107.
12 Gao S,Zhu X,Shi X,et al.Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer:study protocol of a prospective,randomized phase II trial(BRPCNCC-1)[J].Radiat Oncol,2019,14(1):52.
13 Pan L,Fang J,Tong C,et al.Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer:a systematic review and meta-analysis[J].World J Surg Oncol,2019,18(1):1.
14 Sho M,Akahori T,Tanaka T,et al.Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer[J].J Hepatobiliary Pancreat Sci,2013,20(2):197-205.
15 Maurel J,Sánchez-Cabús S,Laquente B,et al.Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer(GEMCAD 10-03 trial)[J].Cancer Chemother Pharmacol,2018,82(6):935-943.
16 Chiaro DM,Soreide K.Trials and tribulations of neoadjuvant therapy in pancreatic cancer[J].Br J Surg,2018,105(11):1387-1389.
17 Ye M,Zhang Q,Chen Y,et al.Neoadjuvant chemotherapy for primary resectable pancreatic cancer:a systematic review and meta-analysis[J].HPB(Oxford),2020,22(6):821-832.
18 Roland CL,Yang AD,Katz MH,et al.Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer[J].Ann Surg Oncol,2015,22(4):1168-1175.
19 Nagakawa Y,Hosokawa Y,Nakayama H,et al.A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement[J].Cancer Chemother Pharmacol,2017,79(5):951-957.
20 Murphy JE,Wo JY,Ryan DP,et al.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer:a phase 2 Clinical Trial[J].JAMA Oncol,2019,5(7):1020-1027.
21 Vidri RJ,Vogt AO,Macgillivray DC,et al.Better defining the role of total neoadjuvant radiation:changing paradigms in locally advanced pancreatic cancer[J].Ann Surg Oncol,2019,26(11):3701-3708.
22 Jang JY,Han Y,Lee H,et al.Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer a prospective,randomized,open-label,multicenter phase 2/3 trial[J].Ann Surg,2018,268(2):215-222.
23 Galindo J,Gabrielli M,Guerra JF,et al.Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma:report of two cases[J].World J Surg Oncol,2013,11:37.
24 Passardi A,Scarpi E,Neri E,et al.Chemoradiotherapy(Gemox Plus Helical Tomotherapy)for unresectable locally advanced pancreatic cancer:a phase II study[J].Cancers(Basel),2019,11(5):663.
25 Pipas JM,Zaki BI,McGowan MM,et al.Neoadjuvant cetuximab,twice-weekly gemcitabine,and intensity-modulated radiotherapy(IMRT)in patients with pancreatic adenocarcinoma[J].Ann Oncol,2012,23(11):2820-2827.
26 Belfiore MP,Ronza FM,Romano F,et al.Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer:our preliminary experience[J].Int J Surg,2015,21(suppl 1):34-39.
27 Yu Y,Zheng P,Chen Y,et al.Advances and challenges of neoadjuvant therapy in pancreatic cancer[J].Asia Pac J Clin Oncol,2020[online ahead of print].

[1]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[2]	王亮亮, 丁高恒, 陈莉莉, 吴建军, 刘玉琴, 魏兴民. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206.
[3]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.
[4]	姚克非,张博淼(综述),崔滨滨(审校). 低位直肠癌选择性侧方淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 69-72.
[5]	刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.
[6]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[7]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[8]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[9]	罗干, 易超, 依马木买买提江·阿布拉, 徐林, 尹继炜, 丁伟. Notch信号通路在胰腺癌中的表达及其作用研究[J]. 实用肿瘤学杂志, 2019, 33(1): 1-7.
[10]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[11]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[12]	杨梅健, 宝莹娜综述, 赵建国审校. 直肠癌的新辅助治疗[J]. 实用肿瘤学杂志, 2016, 30(5): 453-457.
[13]	赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.
[14]	戴猛, 李锐, 刘贵庭, 梁金龙, 冯金发, 徐善勇. 新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析[J]. 实用肿瘤学杂志, 2016, 30(2): 109-113.
[15]	蔡芸芸, 何胜利. 胰腺癌伴肝、左眼眶转移1例[J]. 实用肿瘤学杂志, 2016, 30(2): 140-141.

胰腺癌新辅助治疗的研究现状

Research status of neoadjuvant therapy for pancreatic cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价